Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03029325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Boston Lung Cancer Study (Molecular and Genetic Analysis of Lung Cancer)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Sep 2026 → Sep 2028
See other at-risk trials from Massachusetts General Hospital

Record History

  1. Primary and study completion pushed from Sep 2026 to Sep 2028 Eligibility criteria shortened, about 7 words · Study title expanded, about 4 words Show 2 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Study title expanded, about 4 words
  2. Primary and study completion dates: Sep 2023 to Sep 2026 Enrollment target: 12000 to 15000 · Site contact updatedv6 Show 2 more changesShow less
    • Enrollment target: 12000 to 15000
    • Site contact updated
  3. Primary and study completion dates: Sep 2022 to Sep 2023v5
  4. Enrollment target: 10000 to 12000v4
  5. Re-verified, no change to tracked fieldsv3
  6. Primary completion date: Jun 2017 to Sep 2022 Completion date: Sep 2017 to Sep 2022v2 Show 1 more changeShow less
    • Completion date: Sep 2017 to Sep 2022
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.
Trial Details
NCT Number NCT03029325
Lead Sponsor Massachusetts General Hospital
Collaborators: National Cancer Institute (NCI)
Conditions Lung Cancer
Enrollment 15,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov